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Objective/purpose
TSLP plays a major role in the induction and effector
phases of allergic diseases by acting on dendritic cells,
mast cells (MCs), T cells and CD34
+ hemopoietic pro-
genitor cells. Whereas the cellular origin and the
mechanisms regulating TSLP production are well docu-
mented, little is known about the regulation of TSLP
receptor expression. We analyzed the regulation of
TSLP-R with several cytokines, TLR ligands and drugs
commonly used to treat asthma.
Methods
Neonatal CD34
+ cells were examined by two-colour
analysis for the expression of CD34 and TSLP-R after
48 hours of incubation with or without: 1) cytokines
(IL-1, TNF, IL-4, IFN-g, TGF-b) used alone or in combi-
nation; 2)inflammatory mediators (PGE2, LTC4 and
PGD2); 3) bacterial products (SAC, LPS and PGN); 4)
TLR ligands (TLR3, TLR5, and TLR7); 5) dexametha-
sone and isoproterenol.
Findings
Expression of TSLP-R on CD34
+ cells was markedly
enhanced by IL-1/TNF; this effect was suppressed by
IL-4, IFN-g and TGF-b and augmented by PGE2. TSLP-
R was induced by SAC and PGN but was not affected
by LPS or other TLR ligands. Most interestingly, dexa-
methasone slightly induced TSLP-R and IL-7Ra expres-
sion and markedly increased the effect of IL-1/TNF.
The enhancing effect of dexamethasone was also
observed on CD14
+ and CD56
+ neonatal cells. Isopro-
terenol had no effect on the regulation of TSLP-R.
Deliverables
Taken together, our data may explain the synergistic
effect of IL-1/TNF on the response of CD34
+ cells to
TSLP. They further show that TSLP-R expression is
markedly regulated by the inflammatory and cytokine
environment. The biological consequences of glucocorti-
coid-induced upregulation of TSLP-R will be examined.
Relevance
Currently, there is no disease-modifying treatment for
allergic diseases. Indeed, steroids, the main therapeutic
tool for improving the quality of patients’ life, do not
prevent irreversible tissue-remodeling and the loss of
pulmonary function. Current observations indicate that
steroids upregulate the receptor of pro-inflammatory
cytokine TSLP on the surface of CD34
+ cells. The effect
of current anti-allergic treatment on the proinflamma-
tory activity of CD34
+ cells should be taken into
account and these cells could be considered as target for
the development of novel therapeutic approaches for
atopic diseases.
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